Stem Cells for COVID-19 ARDS
A clinical trial led by Michael Matthay, M.D. at the University of California, San Francisco is exploring the potential of Bone Marrow derived Mesenchymal Stem Cells (MSCs) for COVID-19 pneumonia related Adult Respiratory Distress Syndrome (ARDS). In the treatment arm of the study, patients will receive two intravenous infusions of 2 million MSCs/kg. The study is anticipated to enroll 300 patients in total.
Search our Directory
AABRM Members are not only experts in regenerative medicine but offer a wide range of related products, services and related-procedures in that field. Search our extensive Member Directory to find a Member near you.Member Directory